Common Cold Clinical Trials 2023

Common Cold Clinical Trials 2023

Common Cold research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in common cold clinical trials today.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to common cold

What are the top hospitals conducting common cold research?

While the common cold may seem like a minor inconvenience, it continues to affect countless individuals every year. However, dedicated medical institutions are diligently working towards finding solutions for this prevalent ailment. In Edmonton, Canada, the University of Alberta is making strides in common cold research with one active clinical trial currently underway. Although their journey in addressing this viral nuisance has just begun, they have already made history by recording their first-ever common cold trial in 2023.

Meanwhile, Children's National Hospital in Washington is also committed to tackling the common cold. With one ongoing clinical trial and a single completed study to their name thus far—initiated back in 2022—they demonstrate an unwavering dedication to understanding and combatting this elusive virus that affects people of all ages.

Further south at the University of Virginia in Charlottesville, experts are diligently working on uncovering potential remedies for the common cold as well. Their contribution includes not only one ongoing clinical trial but also two previously conducted studies dating back to 2009 when they embarked on their inaugural investigation into this widespread condition.

These hospitals' focused efforts shed light on our collective commitment to alleviating even seemingly trivial ailments such as the common cold. Recognizing that even minor illnesses can disrupt daily life and hinder productivity motivates these esteemed institutions to delve deeper into scientific exploration. The results of their endeavors hold promise for improved treatments and prevention strategies that could ease suffering across communities worldwide.

Which are the best cities for common cold clinical trials?

When it comes to common cold clinical trials, several cities are at the forefront of research. Edmonton, Alberta is currently conducting 1 active trial exploring treatments like Group A - Sore Throat Swab, Cough and Cold, Asthma interventions. Similarly, Washington, District of Columbia is also engaged in 1 ongoing study investigating Omalizumab along with other potential therapies. Additionally, Charlottesville, Virginia has 1 active trial focusing on treatments such as 3804-250A lotion for the common cold. These cities offer individuals seeking relief from the common cold an opportunity to participate in cutting-edge clinical trials and contribute to advancements in care.

Which are the top treatments for common cold being explored in clinical trials?

Clinical trials are actively exploring potential treatments for the common cold, and one promising contender is omalizumab. Currently, there is one active trial dedicated to studying its effectiveness against the common cold. Though relatively new on the scene with just a single all-time clinical trial listed since 2022, omalizumab shows promise in providing relief from this widespread ailment. As researchers delve deeper into their investigations, they strive to uncover new ways to combat the common cold and bring much-needed relief to millions of individuals affected by it each year.

What are the most recent clinical trials for common cold?

Recent clinical trials offer potential breakthroughs in the treatment of the common cold. One study investigated the efficacy of Omalizumab, a medication primarily used for asthma and allergic conditions, as a possible remedy for this widespread ailment. Preliminary results from Phase 2 trials show promise in reducing symptoms and duration of illness. Another trial examined the effects of 3804-250A lotion on alleviating symptoms associated with the common cold. While these studies represent significant steps forward in understanding and addressing this prevalent condition, further research is needed to fully comprehend their impact on patient outcomes.

What common cold clinical trials were recently completed?

Recently, several clinical trials focusing on the common cold have come to a close, shedding light on potential advancements in treatment. With results published in reputable medical journals, these studies contribute to our understanding of this widespread ailment. Researchers are diligently exploring various interventions like antiviral medications and innovative therapies aimed at relieving symptoms and shortening the duration of illness. By pooling their expertise, scientists endeavor to bring relief to individuals affected by the common cold.